Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28720835 | 1.00 | SIGMAR1 (0.31) | SIGMAR1LMNAMAPTADRA2CHTR2A | |
| SCHEMBL29416082 | 1.00 | SIGMAR1 (0.31) | SIGMAR1LMNAMAPTADRA2CHTR2A | |
| SCHEMBL28712146 | 0.79 | BCHE (0.34) | BCHEACHE | |
| SCHEMBL20117005 | 0.78 | PARP1 (0.32) | HTR2AMAPK8 | |
| SCHEMBL28707242 | 0.77 | HTR2A (0.42) | SIGMAR1HTR2ASLC6A4HTR2BMAPK8 | |
| SCHEMBL29416206 | 0.77 | HTR2A (0.42) | SIGMAR1HTR2ASLC6A4HTR2BMAPK8 | |
| SCHEMBL20089760 | 0.77 | HTR2A (0.42) | SIGMAR1HTR2ASLC6A4HTR2BMAPK8 | |
| SCHEMBL19469910 | 0.76 | AXL (0.44) | — | |
| SCHEMBL29416146 | 0.76 | AXL (0.44) | — | |
| SCHEMBL19469912 | 0.76 | AXL (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114656464-A | 6,7,8, 9-tetrahydro-3H-pyrazolo [4,3-f ] isoquinoline derivatives useful for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-109843888-B | 6, 7, 8, 9-tetrahydro-3H-pyrazolo [4, 3-f ] isoquinoline derivatives useful for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3640251-B1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2021-12-08 | — | — | EP | disclosed |
| US-20210284636-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2021-09-16 | — | — | US | disclosed |
| US-10961241-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2021-03-30 | — | — | US | disclosed |
| US-20200239467-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2020-07-30 | — | — | US | disclosed |
| EP-3640251-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2020-04-22 | — | — | EP | disclosed |
| US-10590130-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-17 | — | — | US | disclosed |
| EP-3433256-B1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVE USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2019-08-07 | — | — | EP | disclosed |
| US-20190100520-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA UK LIMITED (GB) | 2019-04-04 | — | — | US | disclosed |
| WO-2018077630-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239467-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | SIGMAR1 2627/4885LMNA 1007/4885MAPT 1908/4885 |
| US-10961241-B2 | Chemical compounds | MKI67, CCNI, MCL1 | SIGMAR1 2627/4885LMNA 1007/4885MAPT 1908/4885 |
| US-20180111931-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | SIGMAR1 2627/4885LMNA 1007/4885MAPT 1908/4885 |
| US-20190100520-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | SIGMAR1 2627/4885LMNA 1007/4885MAPT 1908/4885 |
| US-10590130-B2 | Chemical compounds | MKI67, CCNI, MCL1 | SIGMAR1 2627/4885LMNA 1007/4885MAPT 1908/4885 |
| US-20210284636-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | SIGMAR1 2627/4885LMNA 1007/4885MAPT 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.